US Says Fed. Circ. Must Show Claim Construction Deference
The government weighed in on Teva Pharmaceuticals USA Inc.'s appeal of a Federal Circuit decision invalidating a patent for its multiple sclerosis drug Copaxone, telling the U.S. Supreme Court on Monday...To view the full article, register now.
Already a subscriber? Click here to view full article